Clomacran

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Clomacran is an antipsychotic drug of the dihydroacridine class, developed in the 1970s by the pharmaceutical company Smith, Kline & French (now GlaxoSmithKline) under the brand names Devryl and Olaxin. It was used to treat schizophrenia in the 1970s. It was withdrawn from the market in the UK, due to liver toxicity, in 1982.

Clomacran is an antipsychotic drug of the dihydroacridine class, developed in the 1970s by the pharmaceutical company Smith, Kline & French (now GlaxoSmithKline) under the brand names Devryl and Olaxin. It was used to treat schizophrenia in the 1970s. It was withdrawn from the market in the UK, due to liver toxicity, in 1982.

Synthesis

Clomacran can be synthesized beginning with 2-chloroacridone (1) which is reacted with a Grignard reagent derived from 3-chloro-N,N-dimethylpropylamine (2) to afford the tertiary carbinol (3). Dehydration by means of acid or simply heat gives the corresponding olefin (4). Catalytic reduction completes the synthesis of clomacran (5).

See also

Chlorprothixene

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370168232 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.